Search: WFRF:(Kayed Hany)
> (2009) >
Expression of FXYD3...
-
Widegren, EmmaLinköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet,Linkoping Univ, Dept Oncol, Inst Clin & Expt Med, SE-58185 Linkoping, Sweden
(author)
Expression of FXYD3 Protein in Relation to Biological and Clinicopathological Variables in Colorectal Cancers
- Article/chapterEnglish2009
Publisher, publication year, extent ...
-
2009-12-02
-
S. Karger AG,2009
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:liu-52911
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-52911URI
-
https://doi.org/10.1159/000263227DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-6939URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Background: FXYD3 is up-/down-regulated in different types of cancers. We examined FXYD3 expression in colorectal cancers and its relationship to biological and clinicopathological variables. Patients and Methods: Expression of FXYD3 protein was immunohistochemically examined in distant normal mucosa (n = 34), adjacent normal mucosa (n = 72), primary tumour (n = 150) and lymph node metastasis (n = 35) from colorectal cancer patients. Results: FXYD3 was highly expressed in primary tumour compared to adjacent normal mucosa (p = 0.02). FXYD3 was or tended to be positively related to the expression of ras (p = 0.02), p53 (p = 0.06), legumain (p = 0.02) and proliferating cell nuclear antigen (p = 0.03). Moreover, there was a higher frequency of strong FXYD3 expression in Dukes A-C tumours than in D tumours (p = 0.04). The strong FXYD3 expression tended to predict worse survival in the patients with Dukes A + B tumour (p = 0.07), while there was no such tendency in the patients with Dukes C + D tumour (p = 0.94). The tumours located in the colon had a higher degree of FXYD3 expression than the tumours located in the rectum (p = 0.05). Conclusion: The FXYD3 was associated with certain biological variables and may be involved in the development of the relative earlier stages of colorectal cancers.
Subject headings and genre
-
Colorectal cancer; FXYD3; Immunohistochemistry
-
MEDICINE
-
MEDICIN
Added entries (persons, corporate bodies, meetings, titles ...)
-
Önnesjö, SofiaLinköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet,Linkoping Univ, Dept Oncol, Inst Clin & Expt Med, SE-58185 Linkoping, Sweden(Swepub:liu)sofon33
(author)
-
Arbman, GunnarÖstergötlands Läns Landsting,Kirurgiska kliniken i Östergötland med verksamhet i Linköping, Norrköping och Motala,Landstinget i Östergötland,Vrinnevi Univ Hosp, Dept Surg, Norrkoping, Sweden
(author)
-
Kayed, HanyUniv Heidelberg, Inst Clin Radiol and Nucl Med, Univ Hosp Mannheim, Heidelberg, Germany
(author)
-
Zentgraf, HanswalterGerman Canc Res Ctr, D-6900 Heidelberg, Germany
(author)
-
Kleeff, JoergTech Univ Munich, Dept Surg, Munich, Germany
(author)
-
Zhang, HongHögskolan i Skövde,Institutionen för vård och natur,Univ Skovde, Sch Life Sci, Skovde, Sweden(Swepub:his)zhah
(author)
-
Sun, Xiao-FengÖstergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Onkologiska kliniken US,Linkoping Univ, Dept Oncol, Inst Clin & Expt Med, SE-58185 Linkoping, Sweden(Swepub:liu)xiasu45
(author)
-
Linköpings universitetInstitutionen för klinisk och experimentell medicin
(creator_code:org_t)
Related titles
-
In:Chemotherapy: S. Karger AG55:6, s. 407-4130009-31571421-9794
Internet link
Find in a library
To the university's database